Trading / Browse Companies / Impel NeuroPharma stock

Impel NeuroPharma Stock

impelnp.comBioTechFounded: 2008Funding to Date: $122.85MM

Impel NeuroPharma is a biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases.

Buy or sell Impel NeuroPharma stock
Register for Details

For more details on financing and valuation for Impel NeuroPharma, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

OverviewFinancingsValuation

Team

Management Team

Jon Congleton
Chief Executive Officer, President & Board Member
John Hoekman Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Ellen Lubman
Chief Business Officer
Scott Youmans
Senior Vice President, Engineering
Lynn Gold Ph.D
Senior Vice President, Regulatory
Meghan Swardstrom
Vice President, Clinical Operations
Mike Malafronte
Vice President of Quality Assurance
Stephen Shrewsbury
Chief Medical Officer

Board Members

Aaron Royston MD
venBio
Ali Satvat
Kohlberg Kravis Roberts
David Allison Ph.D
5AM Ventures
Diane Wilfong
H. Stewart Parker
James Young Ph.D
5AM Ventures
John Hoekman Ph.D
Jon Congleton
Mahendra Shah Ph.D
Vivo Capital
Robert Mittendorff MD
Norwest Venture Partners
Timothy Nelson

Other companies like Impel NeuroPharma in the BioTech sector

Mammoth Biosciences
Sector
BioTech
Last Round Est. Valuation
$1.08B
Ginkgo Bioworks
Sector
BioTech
Last Round Est. Valuation
$4.89B
PROCEPT BioRobotics
Sector
BioTech
Last Round Est. Valuation
$872.62MM
Synthego
Sector
BioTech
Last Round Est. Valuation
$486.63MM
eFFECTOR Therapeutics
Sector
BioTech
Last Round Est. Valuation
$186.12MM
Human Longevity
Sector
BioTech
Last Round Est. Valuation
$50.4MM
Grail
Sector
BioTech
Last Round Est. Valuation
$4.26B
Arsenal Biosciences
Sector
BioTech
Last Round Est. Valuation
$185MM
Caris Life Sciences
Sector
BioTech
 
 

News

Market Screener 10/17/2019
Impel NeuroPharma : Announces Appointment Of Diane Wilfong To Board Of Directors
FinSMEs 12/07/2018
Impel NeuroPharma Closes $67.5M in Series D Financing | FinSMEs
Impel NeuroPharma, a biotech company focused on developing therapies for the treatment of CNS disorders, completed a $67.5m Series D financing

Trending Companies

Frequently Asked Questions